Niranjan Kanesa-thasan - Jul 29, 2022 Form 4 Insider Report for Icosavax, Inc. (ICVX)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Stock symbol
ICVX
Transactions as of
Jul 29, 2022
Transactions value $
-$21,904
Form type
4
Date filed
8/2/2022, 09:37 PM
Previous filing
Feb 14, 2023
Next filing
Nov 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Sale -$4.98K -701 -0.29% $7.11 242K Jul 29, 2022 Direct F1, F2
transaction ICVX Common Stock Sale -$13.3K -2K -0.83% $6.64 240K Aug 1, 2022 Direct F1, F3
transaction ICVX Common Stock Sale -$3.64K -543 -0.23% $6.70 239K Aug 2, 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.93 to $7.75. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.38 to $7.17. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.460 to $6.865. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.